# The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR

> **NCT02493582** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **The First People's Hospital of Changzhou** · enrollment: 400 (estimated)

## Conditions studied

- Adenocarcinoma of Lung

## Interventions

- **BIOLOGICAL:** Cytokine-Induced Killer Cells
- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT02493582
- **Lead sponsor:** The First People's Hospital of Changzhou
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-07
- **Primary completion:** 2030-07
- **Final completion:** 2033-07
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2016-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02493582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02493582, "The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02493582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*